Halozyme Therapeutics (NASDAQ:HALO) Releases FY25 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) updated its FY25 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $4.95-$5.35 for the period, compared to the consensus estimate of $4.83. The company issued revenue guidance of $1.150-$1.225 billion, compared to the consensus revenue estimate of $1.16 billion. Halozyme Therapeutics also updated its FY24 guidance to $4.00-$4.20 EPS.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on HALO. JPMorgan Chase & Co. cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price target for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. HC Wainwright reaffirmed a “buy” rating and set a $68.00 target price on shares of Halozyme Therapeutics in a report on Monday, December 30th. Wells Fargo & Company lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price objective for the company from $58.00 to $62.00 in a research note on Monday, October 7th. Piper Sandler lifted their target price on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research note on Monday, November 4th. Finally, JMP Securities upped their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $61.11.

Halozyme Therapeutics Trading Up 1.3 %

Shares of Halozyme Therapeutics stock opened at $51.19 on Wednesday. The stock has a market capitalization of $6.51 billion, a PE ratio of 16.95, a price-to-earnings-growth ratio of 0.44 and a beta of 1.24. Halozyme Therapeutics has a 52 week low of $33.15 and a 52 week high of $65.53. The stock has a 50 day moving average price of $50.10 and a two-hundred day moving average price of $54.00. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total transaction of $532,600.00. Following the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $9,254,244.56. This trade represents a 5.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.70% of the stock is currently owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.